drugset
drugset / Trial / NCT02749331

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy

NCT02749331 ↗

Phase 1/2 Active not recruiting 35 enrolled Uppsala University
NaSingle-groupOpen-labelTreatment

Summary

An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.

Timeline

Start
2016-03
Primary completion
2025-08
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AdVince Unknown 1e+10 unknown Other
Subject AdVince Unknown 1e+11 unknown Other
Subject AdVince Unknown 3e+11 unknown Other
Subject AdVince Unknown 1e+12 unknown Other

Indications

neuroendocrine neoplasm